In this article, we will delve into the performance of one such AI trading robot, the Swing trader: Deep Trend Analysis (TA) bot, which achieved a remarkable +3.34% gain while trading NVAX (Novavax Inc.) over the course of the previous week. We will analyze the bot's performance based on deep trend analysis and also explore NVAX's recent earnings results.
Deep Trend Analysis and Positive MACD:
The Swing trader: Deep Trend Analysis (TA) bot leverages deep trend analysis techniques to identify potential trading opportunities. In the case of NVAX, the bot took advantage of the Moving Average Convergence Divergence (MACD) turning positive on July 10, 2023. Historical data indicates that when NVAX's MACD has turned positive in the past, the stock continued to rise in 39 out of 44 cases over the following month. This suggests a strong probability of a continued upward trend, with an 89% chance of further gains.
Earnings Results and Market Capitalization:
NVAX released its latest earnings report on May 09, which revealed earnings per share of -341 cents, surpassing the estimated -342 cents. Although the company reported a loss, the results exceeded analysts' expectations, which can be seen as a positive sign for the stock. With 1.23 million shares outstanding, the current market capitalization of NVAX stands at 806.09 million.
Summary:
The performance of the Swing trader: Deep Trend Analysis (TA) AI trading bot on NVAX highlights the potential of utilizing advanced analytics and automation in trading strategies. The bot's ability to identify the positive MACD signal and capitalize on it resulted in a significant gain of +3.34% over the previous week. Moreover, the positive historical correlation between NVAX's MACD turning positive and subsequent stock price increases further reinforces the likelihood of continued upward movement. While NVAX's recent earnings report showed a loss, the fact that it beat analysts' estimates indicates potential strength and resilience within the company.
NVAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 29 cases where NVAX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where NVAX's RSI Oscillator exited the oversold zone, of 33 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Aroon Indicator entered an Uptrend today. In of 149 cases where NVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Momentum Indicator moved below the 0 level on October 16, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on NVAX as a result. In of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for NVAX turned negative on October 09, 2024. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at .
NVAX moved below its 50-day moving average on October 16, 2024 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for NVAX crossed bearishly below the 50-day moving average on October 17, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NVAX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NVAX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.000) is normal, around the industry mean (12.657). P/E Ratio (0.000) is within average values for comparable stocks, (111.595). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.971). NVAX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (2.918) is also within normal values, averaging (225.870).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company which engages in development of novel recombinant vaccines
Industry Biotechnology